Actively Recruiting
Validation of in Vitro Method for Anti-MCPyV Immunotherapy on Patients With Cutaneous Merkel Cell Carcinoma
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2025-11-19
15
Participants Needed
1
Research Sites
100 weeks
Total Duration
On this page
Sponsors
A
Assistance Publique - Hôpitaux de Paris
Lead Sponsor
I
Institut National de la Santé Et de la Recherche Médicale, France
Collaborating Sponsor
AI-Summary
What this Trial Is About
The aim of the study is to test and validate in vitro a cell therapy approach for MCPyV+ Merkel Cell Carcinoma patients.
CONDITIONS
Official Title
Validation of in Vitro Method for Anti-MCPyV Immunotherapy on Patients With Cutaneous Merkel Cell Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients 18 years old or older
- Diagnosed with Merkel cell carcinoma of the skin and currently receiving local treatment, systemic treatment, complementary treatment, or active follow-up
- Informed about the study and not opposed to participation
- Affiliated with a social security scheme or equivalent
You will not qualify if you...
- Currently participating in another interventional clinical trial
- Under guardianship or trusteeship
- Pregnant or breastfeeding
- Refusal to participate
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Dermato-oncology Department, Ambroise Paré Hospital, APHP
Boulogne-Billancourt, France, 92100
Actively Recruiting
Research Team
A
Astrid Blom, MD
CONTACT
Y
Yassine Taoufik, MD, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here